“It’s quite an exceptional company with a medical advisory board of the who’s who of the cardiovascular space,” Pachacz says.
He says AVR has had some exceptionally good results in an early feasibility study with plans for a pivotal study involving around 200 patients.
“There’s two main competitors – Edwards Lifesciences and Medtronic,” he says.“So this company will probably get acquired at some point by one of those two companies, I would’ve thought”
———————————————
That planned pivotal study patient number of (only) 200 is new to me, much smaller than 1000+ patients I have seen mentioned elsewhere on this forum. Wonder if that would lead to an early 2025 FDA approval perhaps.
- Forums
- ASX - By Stock
- AVR
- For those who are interested
For those who are interested, page-10
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$18.00 |
Change
-0.300(1.64%) |
Mkt cap ! $346.0M |
Open | High | Low | Value | Volume |
$18.29 | $18.30 | $17.65 | $181.7K | 10.18K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 30 | $17.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.00 | 499 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30 | 17.720 |
1 | 793 | 17.660 |
1 | 39 | 17.650 |
3 | 1007 | 17.550 |
1 | 1 | 17.510 |
Price($) | Vol. | No. |
---|---|---|
18.000 | 499 | 1 |
18.050 | 550 | 1 |
18.300 | 313 | 2 |
18.500 | 43 | 1 |
18.690 | 550 | 1 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |